Breaking Updates in Hematological-Oncology

The American Society of Hematology (ASH) 2021 Annual Meeting and Exposition was held in Atlanta on the 11-14 December. ASH has successfully honed the hybrid model and showcased outstanding leaps in understanding and treatment in 2021, across malignancies. Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.
View all videos

ASH 2021

The 63rd ASH Annual Meeting and Exposition
11–14 December 2021 | Atlanta, GA

💥New: Phase III INDEPENDENCE trial of luspatercept in patients with TD #Myelofibrosis on JAKi therapy💥

Ruben Mesa (@mpdrc) of @UTHealthSAMDA talks on the rationale & design of the currently enrolling study: http://ow.ly/4I5F50HzL3b

#ASH21 #HemOnc #MPNsm #TrialUpdate #CTSM

The latest Lymphoma: Today! https://paper.li/chanyooncheah/1505376789?edition_id=e9b006b0-7db6-11ec-aab8-fa163ed80008 Thanks to @VJHemOnc @smbenlazar @lymphomahub #lymphoma #lymsm

The 2022 4th European CAR T-Cell Meeting is fast approaching – are you ready to be a part of this great experience 🤩? Stay tuned with us @VJHemOnc for regular updates!

@TheEBMT @EHA_Hematology #CART22 #CARTtherapy #ImmunoOnc #HemOnc #tcellrx #MMsm #LYMsm #AMLsm #CARTcell

Today is #BPDCNDay {1-23, #CD123}. Please help me raise awareness for research&novel therapeutics for our patients,families&caregivers facing #BPDCN. I have dedicated my life & career for this cause&will always keep going for you! @lane_andy @JoeKhouryMD @sanamloghavi @tmprowell

4

A study of 61,437 people with myeloma: 3783 from @MayoClinic and 57,654 from SEER Registry shows remarkable improvement in overall survival of myeloma over time. @MoritzBinderMD @LeukemiaJnl @MayoCancerCare @MayoMyeloma https://www.nature.com/articles/s41375-021-01453-5

Load More...

ASH 2021

The 63rd ASH Annual Meeting and Exposition
11–14 December 2021 | Atlanta, GA

Breaking Updates in Hematological-Oncology

The American Society of Hematology (ASH) 2021 Annual Meeting and Exposition was held in Atlanta on the 11-14 December. ASH has successfully honed the hybrid model and showcased outstanding leaps in understanding and treatment in 2021, across malignancies. Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.
View all videos

💥New: Phase III INDEPENDENCE trial of luspatercept in patients with TD #Myelofibrosis on JAKi therapy💥

Ruben Mesa (@mpdrc) of @UTHealthSAMDA talks on the rationale & design of the currently enrolling study: http://ow.ly/4I5F50HzL3b

#ASH21 #HemOnc #MPNsm #TrialUpdate #CTSM

The latest Lymphoma: Today! https://paper.li/chanyooncheah/1505376789?edition_id=e9b006b0-7db6-11ec-aab8-fa163ed80008 Thanks to @VJHemOnc @smbenlazar @lymphomahub #lymphoma #lymsm

The 2022 4th European CAR T-Cell Meeting is fast approaching – are you ready to be a part of this great experience 🤩? Stay tuned with us @VJHemOnc for regular updates!

@TheEBMT @EHA_Hematology #CART22 #CARTtherapy #ImmunoOnc #HemOnc #tcellrx #MMsm #LYMsm #AMLsm #CARTcell

Today is #BPDCNDay {1-23, #CD123}. Please help me raise awareness for research&novel therapeutics for our patients,families&caregivers facing #BPDCN. I have dedicated my life & career for this cause&will always keep going for you! @lane_andy @JoeKhouryMD @sanamloghavi @tmprowell

4

A study of 61,437 people with myeloma: 3783 from @MayoClinic and 57,654 from SEER Registry shows remarkable improvement in overall survival of myeloma over time. @MoritzBinderMD @LeukemiaJnl @MayoCancerCare @MayoMyeloma https://www.nature.com/articles/s41375-021-01453-5

Load More...

post-ASH 2021 iwAL Virtual Workshop - apply for registration

Register for the post-ASH 2021 iwMPNs Virtual Workshop

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter